A citation-based method for searching scientific literature

Marianne Labussière, Blandine Boisselier, Karima Mokhtari, Anna-Luisa Di Stefano, Anais Rahimian, Marta Rossetto, Pietro Ciccarino, Olivier Saulnier, Rosina Paterra, Yannick Marie, Gaetano Finocchiaro, Marc Sanson. Neurology 2014
Times Cited: 123







List of co-cited articles
746 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.
Jeanette E Eckel-Passow, Daniel H Lachance, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Hugues Sicotte, Melike Pekmezci, Terri Rice, Matt L Kosel, Ivan V Smirnov,[...]. N Engl J Med 2015
925
43

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Patrick J Killela, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan H Friedman, Henry Friedman, Gary L Gallia, Beppino C Giovanella,[...]. Proc Natl Acad Sci U S A 2013
841
43

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
39

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
27

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
Roger Stupp, Warren P Mason, Martin J van den Bent, Michael Weller, Barbara Fisher, Martin J B Taphoorn, Karl Belanger, Alba A Brandes, Christine Marosi, Ulrich Bogdahn,[...]. N Engl J Med 2005
27

IDH1 and IDH2 mutations in gliomas.
Hai Yan, D Williams Parsons, Genglin Jin, Roger McLendon, B Ahmed Rasheed, Weishi Yuan, Ivan Kos, Ines Batinic-Haberle, Siân Jones, Gregory J Riggins,[...]. N Engl J Med 2009
27

TERT promoter mutations in primary and secondary glioblastomas.
Naosuke Nonoguchi, Takashi Ohta, Ji-Eun Oh, Young-Ho Kim, Paul Kleihues, Hiroko Ohgaki. Acta Neuropathol 2013
144
26

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J Brat, Roel G W Verhaak, Kenneth D Aldape, W K Alfred Yung, Sofie R Salama, Lee A D Cooper, Esther Rheinbay, C Ryan Miller, Mark Vitucci, Olena Morozova,[...]. N Engl J Med 2015
26

The somatic genomic landscape of glioblastoma.
Cameron W Brennan, Roel G W Verhaak, Aaron McKenna, Benito Campos, Houtan Noushmehr, Sofie R Salama, Siyuan Zheng, Debyani Chakravarty, J Zachary Sanborn, Samuel H Berman,[...]. Cell 2013
25

TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations.
M Labussière, A L Di Stefano, V Gleize, B Boisselier, M Giry, S Mangesius, A Bruno, R Paterra, Y Marie, A Rahimian,[...]. Br J Cancer 2014
101
25

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas.
Patrick J Killela, Christopher J Pirozzi, Patrick Healy, Zachary J Reitman, Eric Lipp, B Ahmed Rasheed, Rui Yang, Bill H Diplas, Zhaohui Wang, Paula K Greer,[...]. Oncotarget 2014
159
24

TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Matthias Simon, Ismail Hosen, Konstantinos Gousias, Sivaramakrishna Rachakonda, Barbara Heidenreich, Marco Gessi, Johannes Schramm, Kari Hemminki, Andreas Waha, Rajiv Kumar. Neuro Oncol 2015
102
24

TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
24

MGMT gene silencing and benefit from temozolomide in glioblastoma.
Monika E Hegi, Annie-Claire Diserens, Thierry Gorlia, Marie-France Hamou, Nicolas de Tribolet, Michael Weller, Johan M Kros, Johannes A Hainfellner, Warren Mason, Luigi Mariani,[...]. N Engl J Med 2005
21

Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma.
Michele Ceccarelli, Floris P Barthel, Tathiane M Malta, Thais S Sabedot, Sofie R Salama, Bradley A Murray, Olena Morozova, Yulia Newton, Amie Radenbaugh, Stefano M Pagnotta,[...]. Cell 2016
891
21

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Hideyuki Arita, Yoshitaka Narita, Shintaro Fukushima, Kensuke Tateishi, Yuko Matsushita, Akihiko Yoshida, Yasuji Miyakita, Makoto Ohno, V Peter Collins, Nobutaka Kawahara,[...]. Acta Neuropathol 2013
219
20

Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Sabine Spiegl-Kreinecker, Daniela Lötsch, Bahil Ghanim, Christine Pirker, Thomas Mohr, Magdalena Laaber, Serge Weis, Alfred Olschowski, Gerald Webersinke, Josef Pichler,[...]. Neuro Oncol 2015
69
27

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
Robert J A Bell, H Tomas Rube, Alex Kreig, Andrew Mancini, Shaun D Fouse, Raman P Nagarajan, Serah Choi, Chibo Hong, Daniel He, Melike Pekmezci,[...]. Science 2015
285
19

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
Christian Koelsche, Felix Sahm, David Capper, David Reuss, Dominik Sturm, David T W Jones, Marcel Kool, Paul A Northcott, Benedikt Wiestler, Katja Böhmer,[...]. Acta Neuropathol 2013
185
18

Frequency of TERT promoter mutations in human cancers.
João Vinagre, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima,[...]. Nat Commun 2013
505
18

The 2007 WHO classification of tumours of the central nervous system.
David N Louis, Hiroko Ohgaki, Otmar D Wiestler, Webster K Cavenee, Peter C Burger, Anne Jouvet, Bernd W Scheithauer, Paul Kleihues. Acta Neuropathol 2007
17

An integrated genomic analysis of human glioblastoma multiforme.
D Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J Leary, Philipp Angenendt, Parminder Mankoo, Hannah Carter, I-Mei Siu, Gary L Gallia,[...]. Science 2008
16

TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mohamed Ali Mosrati, Annika Malmström, Malgorzata Lysiak, Adam Krysztofiak, Martin Hallbeck, Peter Milos, Anna-Lotta Hallbeck, Charlotte Bratthäll, Michael Strandéus, Marie Stenmark-Askmalm,[...]. Oncotarget 2015
62
25

A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Hideyuki Arita, Kai Yamasaki, Yuko Matsushita, Taishi Nakamura, Asanao Shimokawa, Hirokazu Takami, Shota Tanaka, Akitake Mukasa, Mitsuaki Shirahata, Saki Shimizu,[...]. Acta Neuropathol Commun 2016
110
16

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Marc Sanson, Yannick Marie, Sophie Paris, Ahmed Idbaih, Julien Laffaire, François Ducray, Soufiane El Hallani, Blandine Boisselier, Karima Mokhtari, Khe Hoang-Xuan,[...]. J Clin Oncol 2009
675
14

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, Victoria Wang, Yuan Qi, Matthew D Wilkerson, C Ryan Miller, Li Ding, Todd Golub, Jill P Mesirov,[...]. Cancer Cell 2010
14


TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.
Barbara Heidenreich, P Sivaramakrishna Rachakonda, Ismail Hosen, Florian Volz, Kari Hemminki, Astrid Weyerbrock, Rajiv Kumar. Oncotarget 2015
54
22

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
Jeremy Schwartzentruber, Andrey Korshunov, Xiao-Yang Liu, David T W Jones, Elke Pfaff, Karine Jacob, Dominik Sturm, Adam M Fontebasso, Dong-Anh Khuong Quang, Martje Tönjes,[...]. Nature 2012
12

TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.
P Sivaramakrishna Rachakonda, Ismail Hosen, Petra J de Verdier, Mahdi Fallah, Barbara Heidenreich, Charlotta Ryk, N Peter Wiklund, Gunnar Steineck, Dirk Schadendorf, Kari Hemminki,[...]. Proc Natl Acad Sci U S A 2013
205
12

Mutational landscape and clonal architecture in grade II and III gliomas.
Hiromichi Suzuki, Kosuke Aoki, Kenichi Chiba, Yusuke Sato, Yusuke Shiozawa, Yuichi Shiraishi, Teppei Shimamura, Atsushi Niida, Kazuya Motomura, Fumiharu Ohka,[...]. Nat Genet 2015
428
12

Specific association of human telomerase activity with immortal cells and cancer.
N W Kim, M A Piatyszek, K R Prowse, C B Harley, M D West, P L Ho, G M Coviello, W E Wright, S L Weinrich, J W Shay. Science 1994
12

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
Roger Stupp, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin J B Taphoorn, Robert C Janzer, Samuel K Ludwin, Anouk Allgeier, Barbara Fisher, Karl Belanger,[...]. Lancet Oncol 2009
11

Cancer-associated TERT promoter mutations abrogate telomerase silencing.
Kunitoshi Chiba, Joshua Z Johnson, Jacob M Vogan, Tina Wagner, John M Boyle, Dirk Hockemeyer. Elife 2015
139
11

Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Melike Pekmezci, Terri Rice, Annette M Molinaro, Kyle M Walsh, Paul A Decker, Helen Hansen, Hugues Sicotte, Thomas M Kollmeyer, Lucie S McCoy, Gobinda Sarkar,[...]. Acta Neuropathol 2017
146
11

Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma.
Xiaoli Liu, Guojun Wu, Yuan Shan, Christian Hartmann, Andreas von Deimling, Mingzhao Xing. Cell Cycle 2013
95
10

Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.
Yinghui Li, Qi-Ling Zhou, Wenjie Sun, Prashant Chandrasekharan, Hui Shan Cheng, Zhe Ying, Manikandan Lakshmanan, Anandhkumar Raju, Daniel G Tenen, Shi-Yuan Cheng,[...]. Nat Cell Biol 2015
115
10

IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Chao Lu, Patrick S Ward, Gurpreet S Kapoor, Dan Rohle, Sevin Turcan, Omar Abdel-Wahab, Christopher R Edwards, Raya Khanin, Maria E Figueroa, Ari Melnick,[...]. Nature 2012
9

Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.
Pedro Castelo-Branco, Sanaa Choufani, Stephen Mack, Denis Gallagher, Cindy Zhang, Tatiana Lipman, Nataliya Zhukova, Erin J Walker, Dianna Martin, Diana Merino,[...]. Lancet Oncol 2013
148
9

TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.
Miguel Melo, Adriana Gaspar da Rocha, João Vinagre, Rui Batista, Joana Peixoto, Catarina Tavares, Ricardo Celestino, Ana Almeida, Catarina Salgado, Catarina Eloy,[...]. J Clin Endocrinol Metab 2014
296
9

High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Jean Charles Nault, Maxime Mallet, Camilla Pilati, Julien Calderaro, Paulette Bioulac-Sage, Christophe Laurent, Alexis Laurent, Daniel Cherqui, Charles Balabaud, Jessica Zucman-Rossi. Nat Commun 2013
359
9

TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Klaus G Griewank, Rajmohan Murali, Joan Anton Puig-Butille, Bastian Schilling, Elisabeth Livingstone, Miriam Potrony, Cristina Carrera, Tobias Schimming, Inga Möller, Marion Schwamborn,[...]. J Natl Cancer Inst 2014
147
9

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Sumit Borah, Linghe Xi, Arthur J Zaug, Natasha M Powell, Garrett M Dancik, Scott B Cohen, James C Costello, Dan Theodorescu, Thomas R Cech. Science 2015
186
9

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
9

cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Daniel J Brat, Kenneth Aldape, Howard Colman, Eric C Holland, David N Louis, Robert B Jenkins, B K Kleinschmidt-DeMasters, Arie Perry, Guido Reifenberger, Roger Stupp,[...]. Acta Neuropathol 2018
244
9

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Sevin Turcan, Daniel Rohle, Anuj Goenka, Logan A Walsh, Fang Fang, Emrullah Yilmaz, Carl Campos, Armida W M Fabius, Chao Lu, Patrick S Ward,[...]. Nature 2012
8


Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.
Dominik Sturm, Hendrik Witt, Volker Hovestadt, Dong-Anh Khuong-Quang, David T W Jones, Carolin Konermann, Elke Pfaff, Martje Tönjes, Martin Sill, Sebastian Bender,[...]. Cancer Cell 2012
8

International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading.
David N Louis, Arie Perry, Peter Burger, David W Ellison, Guido Reifenberger, Andreas von Deimling, Kenneth Aldape, Daniel Brat, V Peter Collins, Charles Eberhart,[...]. Brain Pathol 2014
363
8

TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
Isaac Kinde, Enrico Munari, Sheila F Faraj, Ralph H Hruban, Mark Schoenberg, Trinity Bivalacqua, Mohamad Allaf, Simeon Springer, Yuxuan Wang, Luis A Diaz,[...]. Cancer Res 2013
162
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.